English
Regional settings| Spread | 0.29 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 6.03 |
| Open | 6.17 |
| 1-Year Change | -59.75% |
| Day's Range | 6.17 - 6.28 |
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The Company's AMPPLIFY technology uses selectively-sized nanoparticles that each have a proprietary coating. Its Preclinical Development Programs include rTKI Program for Retinal Diseases (KPI-285/KPI-286), SEGRM Program and Surface Targeted Steroid Program (KPI-333).
BRIEF: For the nine months ended 30 September 2021, Kala Pharmaceuticals Inc revenues increased from $4.1M to $9.4M. Net loss increased 30% to $95M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 48% to $70.6M (expense), Stock-Based Compensation increase of 50% to $10.4M (expense).
